Gal alpha(1-3) core 6-Fucosylated N-Glycan 2AB (500pmol/vial)>98.0%(HPLC)1vial

4-Naphthalen-1-yl-thiazol-2-ylamine, 95.0%, 2.5g

2-(Cyclobutylidenemethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 97%, 500mg

L-(+)-(2-Chlorophenyl)glycine, 95.0%, 25g

1-(4-Chloro-6-fluorobenzo[d]thiazol-2-yl)azetidin-3-ol, 1g

(2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(morpholino)methanone, 95.0%, 25g

4-(2,6-Dimethyltetrahydro-2H-pyran-4-yl)pyridine 1-oxide, 250mg

3-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, 97%, 250mg

2-Chloro-7-methyl-7H-purine, 97%, 100mg

N-(3-pyridinylmethyl)-2-propanamine dihydrochloride, 95.0%, 5g

(S)-tert-Butyl 2-carbamoylazetidine-1-carboxylate, 95.0%, 500mg

1-Phenyl-3-(piperidin-1-yl)propan-1-one hydrochloride, 95.0%, 250mg

tert-Butyl (3-chloropropyl)(methyl)carbamate, 95.0%, 10g